Catch up on any of the neurology headlines you may have missed in September 2026, compiled into 1 place by the NeurologyLive® team.
News|Articles|June 23, 2026
Pipeline Review: Alzheimer Disease Therapies by Mechanism of Action
Author(s)Louie Pasculli
Fact checked by: Marco Meglio
The 2026 Alzheimer disease drug development landscape highlights a growing shift toward diverse disease-modifying strategies, from amyloid and tau targeting to metabolic and neuroprotective approaches.
Advertisement
Advertisement
June is Alzheimer’s & Brain Awareness Month, an annual observance dedicated to raising awareness of Alzheimer disease (AD), related dementias, and the importance of maintaining brain health across the lifespan. Established by the Alzheimer’s Association in 2014, the campaign highlights the growing burden of AD while promoting education on risk reduction, early detection, diagnosis, and advances in research and treatment.
Related to this article
Carlos Cruchaga, PhD, director of the NeuroGenomics and Informatics Center at Washington University, discusses emerging blood-based biomarkers for monitoring biological and cognitive responses to lecanemab treatment in Alzheimer disease.
Here's some of what is coming soon to NeurologyLive® this week.
Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending October 2, 2026.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Newly announced Phase 4 THRIVE trial results showed most patients who previously had an inadequate response to a CGRP-targeting therapy improved with eptinezumab over 24 weeks.
Phase 3 ARISE trial results show solengepras 150 mg significantly reduced OFF time and improved motor and non-motor symptoms in Parkinson disease.
An MDS 2026 plenary speaker discusses the evolving role of infusion therapies, deep brain stimulation, and focused ultrasound in Parkinson disease, including when to consider device-aided therapies and how treatment selection can be individualized.
Advertisement
Advertisement